scispace - formally typeset
F

Futoshi Muranaka

Researcher at Shinshu University

Publications -  23
Citations -  113

Futoshi Muranaka is an academic researcher from Shinshu University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 3, co-authored 18 publications receiving 77 citations.

Papers
More filters
Journal ArticleDOI

Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases.

TL;DR: AMM patients treated by curative surgery can expect long-term survival, although the usefulness of adjuvant chemotherapy for AMM patients is controversial.
Journal ArticleDOI

A Comparative Immunohistochemical Study of Anal Canal Epithelium in Humans and Swine, Focusing on the Anal Transitional Zone Epithelium and the Anal Glands.

TL;DR: The MUC5AC+/SOX2+/M UC5AC−/MUC2−/CDX2− /CDx2− profile of the ATZ epithelium and anal glands is a useful feature for diagnosing adenocarcinoma arising from these regions.
Journal ArticleDOI

Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer.

TL;DR: In this article, the significance of systemic inflammation-related variables and clinicopathologic characteristics as predictive markers of response to nivolumab monotherapy in patients with advanced gastric cancer was analyzed.
Journal ArticleDOI

Three Cases of Pseudo-Meigs' Syndrome Secondary to Ovarian Metastases from Colorectal Cancer.

TL;DR: In patients with suspected pseudo-Meigs' syndrome secondary to ovarian metastasis of colorectal cancer, operation including oophorectomy may reduce pleural effusions and/or ascites and improve the general condition.
Journal ArticleDOI

Low­dose trametinib and Bcl­xL antagonist have a specific antitumor effect in KRAS­mutated colorectal cancer cells.

TL;DR: It is suggested that a low dose of trametinib (10 nM), rather than the usual dose of 100–nM, in combination with ABT263 can overcome the resistance to apoptosis induced by Bcl‑xL expression, which occurs concurrently with p‑ERK suppression in KRAS‑mutant cells.